Complete Genomics, Inc. is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center. Its customers include some of the global academic and government research centers and biopharmaceutical companies. Effective March 18, 2013, BGI-Shenzhen announced that through its wholly-owned subsidiary, Beta Acquisition Corporation, it has completed the acquisition of the Company.
Industry, Sector and Symbol:
- Sector: N/A
- Industry: N/A
- Sub-Industry: N/A
- Symbol: NASDAQ:GNOM
- CUSIP: N/A
- Web: N/A
P/E:- Trailing P/E Ratio:
- P/E Growth:
Dividend:
Frequently Asked Questions for Complete Genomics (NASDAQ:GNOM)
What is Complete Genomics' stock symbol?
Complete Genomics trades on the NASDAQ under the ticker symbol "GNOM."
Who are some of Complete Genomics' key competitors?
Some companies that are related to Complete Genomics include Orange Belgium (MBSRF), Apple (AAPL), Alphabet (GOOGL), Alphabet (GOOG), Amazon.com (AMZN), Facebook (FB), Premier Foods Spon (PRRFY), Berkshire Hathaway (BRK-A), Nestle SA (NSRGY), Microsoft Corporation (MSFT), Industrial & Cmrcl Bnk f China Ltd (IDCBY), RDS-A (RDS-A), Roche Holding (RHHBY), Comcast Corporation (CMCSA), Cisco Systems (CSCO), Amgen (AMGN), LVMH Moet Hennessy Louis Vuitton SE (LVMUY) and Inditex (IDEXY).
How do I buy Complete Genomics stock?
Shares of Complete Genomics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Complete Genomics' stock price today?
One share of Complete Genomics stock can currently be purchased for approximately $3.14.
MarketBeat Community Rating for Complete Genomics (NASDAQ GNOM)MarketBeat's community ratings are surveys of what our community members think about Complete Genomics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Complete Genomics (NASDAQ:GNOM) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | No ratings tracked in the last 12 months. |
| Consensus Rating: | N/A (Score: NaN) |
| Consensus Price Target: | N/A |
Analysts' Ratings History for Complete Genomics (NASDAQ:GNOM)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Complete Genomics (NASDAQ:GNOM)Earnings History by Quarter for Complete Genomics (NASDAQ GNOM)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 11/9/2012 | Q312 | ($0.52) | ($0.52) | $8.05 million | $7.27 million | View | N/A |  |
(Data available from 1/1/2011 forward)
Earnings Estimates for Complete Genomics (NASDAQ:GNOM)No earnings estimates for this company have been tracked by MarketBeat.com
Dividend History for Complete Genomics (NASDAQ:GNOM)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Complete Genomics (NASDAQ:GNOM)
No insider trades for this company have been tracked by MarketBeat.com
Headline Trends for Complete Genomics (NASDAQ:GNOM)
Latest Headlines for Complete Genomics (NASDAQ:GNOM)
| Source: |
|
No headlines for this company have been tracked by MarketBeat.com
Complete Genomics (GNOM) Chart for Monday, July, 24, 2017
